POST Online Media Lite Edition



 

Pfizer Q4 revenues totaled $14 billion, up 7%

Staff writer |
Pfizer reported financial results for fourth quarter 2015. Reported revenues totaled $14 billion, an increase of $930 million, or 7%.

Article continues below






This reflects operational growth of $1.9 billion, or 14%, partially offset by the unfavorable impact of foreign exchange of $934 million, or 7%.

Excluding the impact of legacy Hospira operations of $1.2 billion, foreign exchange and, to a lesser extent, the vaccines acquired from Baxter International of $35 million, Pfizer-standalone revenues increased by $646 million operationally, or 5%.

Operational revenue growth in developed markets was driven primarily by the inclusion of $1.1 billion of revenues from legacy Hospira operations and continued strong performance of several key products, notably Prevnar 13 in adults and Ibrance in the U.S., Eliquis globally as well as Xeljanz and Lyrica primarily in the U.S.

In emerging markets, revenues increased 5% operationally, favorably impacted by the addition of legacy Hospira operations, which contributed $73 million, as well as the performance of Prevenar 13 and certain other products.

Operational revenue growth was partially offset primarily by the loss of exclusivity and associated generic competition for Celebrex in the U.S. and certain other developed markets, Lyrica in certain developed Europe markets and Zyvox in the U.S.


What to read next

Pfizer standalone revenues in 2016 grew 5% operationally
Pfizer Q3 revenues increased 1%
Pfizer Q1 net income increased year-over-year